Background and Objectives: Polycystic ovarian syndrome (PCOS) is a widespread endocrine disorder affecting 5–18% of females in their childbearing age. The aim of this study is to assess the efficacy of combining a low dosage of human chorionic gonadotropin (HCG) along with clomiphene citrate (CC) for stimulating ovulation in infertile women diagnosed with CC-resistant PCOS. Materials and Methods: A randomized controlled trial was carried out on 300 infertile CC-resistant PCOS women. All participants were assigned to two groups: the CC-HCG group and the CC-Placebo group. Subjects in the CC-HCG group were given CC (150 mg/day for 5 days starting on the 2nd day of the cycle) and HCG (200 IU/day SC starting on the 7th day of the cycle). Subjects in the CC-Placebo group were given CC and a placebo. The number of ovarian follicles > 18 mm, cycle cancellation rate, endometrial thickness, ovulation rate, clinical pregnancy rate, and occurrence of early ovarian hyper-stimulation syndrome were all outcome variables in the primary research. Results: Data from 138 individuals in the CC-HCG group and 131 participants in the CC-Placebo group were subjected to final analysis. In comparison to the CC-Placebo group, the cycle cancellation rate in the CC-HCG group was considerably lower. The CC-HCG group exhibited a substantial increase in ovarian follicles reaching > 18 mm, endometrial thickness, and ovulation rate. The clinical pregnancy rate was higher in the CC-HCG group (7.2% vs. 2.3%; CC-HCG vs. CC-Placebo). Upon adjusting for BMI and age, the findings of our study revealed that individuals in the CC-HCG group who had serum prolactin levels below 20 (ng/mL), secondary infertility, infertility duration less than 4 years, baseline LH/FSH ratios below 1.5, and serum AMH levels more than 4 (ng/mL) had a higher likelihood of achieving pregnancy. In the CC-Placebo group, there was a greater prediction of clinical pregnancy for those with serum AMH (<4), primary infertility, serum prolactin ≤ 20 (ng/mL), baseline LH/FSH < 1.5, and infertility duration < 4 years. Conclusions: The use of a small dose of HCG along with CC appeared to be an effective treatment in reducing cycle cancelation, improving the clinical pregnancy rate and ovulation rate in CC-resistant PCOS patients. The trial was registered with Clinical Trials.gov, identifier NCT02436226
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms that profoundly impact patients' quality of life. While pharmacological therapies such as levodopa remain the mainstay of treatment, their long-term use is often limited by motor complications. Device-based interventions, including deep brain stimulation (DBS) and continuous dopaminergic infusions, have emerged as alternatives, promising sustained symptomatic control and reduced medication-related side effects. This systematic review and meta-analysis evaluate the comparative efficacy, safety, and cost-effectiveness of device-based interventions versus pharmacological therapies in the management of advanced PD. A comprehensive search was conducted across multiple databases to identify randomized controlled trials, observational studies, and systematic reviews. Primary outcomes included motor function improvement, quality of life, and adverse events. Meta-analyses were performed, and subgroup analyses explored the effectiveness of specific interventions. Device-based interventions demonstrated superior efficacy over pharmacological therapies, with a pooled effect size (Cohen's d) of 1.12 (95% confidence interval (CI): 0.94-1.29) for motor symptom control and quality of life improvements. Subgroup analyses showed DBS and levodopa-carbidopa intestinal gel to be particularly effective, with levodopa-carbidopa intestinal gel showing a Cohen's d of 1.25 (95% CI: 0.91-1.58). Device-based therapies also reduced medication dosages and associated motor complications. Sensitivity analyses confirmed the robustness of these findings, and no significant publication bias was detected. However, gaps remain in understanding the long-term outcomes and cost-effectiveness of these interventions. Device-based interventions, especially DBS and levodopa-carbidopa intestinal gel, offer superior symptom control and quality of life improvements compared to traditional pharmacological therapies in advanced PD. These findings support the integration of device-based therapies into personalized treatment strategies. Further research is needed to explore long-term outcomes and establish standardized guidelines for their implementation in clinical practice.
BACKGROUND: Drug-related problems (DRPs) significantly threaten the safety of the elderly. In order to improve pharmacists' ability to minimize these events, novel educational interventions that consider the current challenges in clinical practice are crucial. OBJECTIVES: The primary objective is to assess the impact of two unique educational interventions on pharmacists' ability to identify DRPs. METHOD: A total of 127 community pharmacies in the United Arab Emirates (UAE) were recruited and randomly allocated to one of three arms using a 1:1:1 allocation ratio. While a series of clinical case scenarios (N = 24) related to elderly care were established and validated and sent to pharmacists in Active Group A over a 3-month period, lengthy research articles focused on medication safety in elderly were emailed to pharmacists in Active Group B. The control group pharmacist received no intervention. Then, pharmacists self-reported the number, categories, and severity of DRPs and pharmacist recommendations. RESULTS: The incidence of DRPs identified by pharmacists was 10.8% in Active Group A, 2.0% in the Control Group (p = 0.011), and 3.8% in Active Group B (p = 0.014). A significant difference was observed in the proportion of DRP types between Active Group A and the Control Group. The most common DRPs in Active Group A were avoidable medication (14.7%) and untreated disease (9.2%). Pharmacists in Active Group A (37.2%) and Active Group B (32.3%) most commonly intervened by recommending the cessation of medication, while the most common intervention in the Control Group was recommending a decrease in dose (29.8%). The mean cost reduction per patient was highest in Active Group A (31.3 ±11.8 $), followed by Active Group B (20.8 ±8.6 $) and the Control Group (19.6 ±9.5 $). The mean time needed to resolve a DRP was shortest in Active Group A (7.3 ±3.5 minutes), followed by Active Group B (9.8 ±4.2 minutes) and the Control Group (9.8 ±5.7 minutes). CONCLUSION: Using WhatsApp to deliver clinical scenarios was effective in improving pharmacists' ability to identify and address DRPs in elderly patients, resulting in faster resolution and higher cost savings.
Background and Objectives: Compared to other subjects, obese people have inferior trunk muscle endurance and balance. A modern method of neuro-muscular training called whole body vibration (WBV) may improve trunk muscle endurance and balance. This study evaluates the impact of a 4-week WBV program on trunk endurance and balance in obese female students. Materials and Methods: Sixty participants from 18 to 25 years of age and with BMI values ≥ 30 were randomly distributed into two equal groups: Group A (WBV group), who received 4 min of WBV, and Group B (sham WBV group), who received WBV with a turn-off device. The training was conducted two days/week for six weeks. Trunk endurance was evaluated using the Sorensen Test (ST) and Trunk Flexor Endurance Test (TFET). The Single-Leg Test (SLT) was used to assess static balance, while the Biodex Stability System measured dynamic balance. Results: The current study demonstrated no significant differences (p > 0.05) in pre-treatment variables between Groups A and B. Post-treatment, Group A showed a significantly higher duration of the Sorensen test, TFET and SLS than Group B (p < 0.001). Moreover, Group A showed significantly lower dynamic balance (p < 0.001) than Group B. Conclusions: WBV has a short-term effect on trunk endurance and balance in obese female students. WBV can be added to the rehabilitation program for obese subjects with deficits in trunk endurance and balance.
International Journal of Physical Therapy Research & Practice · مجلد 3 (9) · 369-378
Background: Smoking is a leading cause of respiratory muscle weakness and diminished lung function. Inspiratory Muscle Training (IMT), particularly with Tapered Flow Resistive Loading (TFRL), is a promising non-pharmacological intervention aimed at enhancing respiratory muscle strength. This randomized controlled trial (RCT) aims to evaluate whether IMT with TFRL can significantly improve respiratory muscle strength and lung function in smokers. Methodology: The study enrolled 60 adult smokers aged 18-60 years, with a smoking history of at least five years and mild to moderate lung impairment, defined by a baseline Forced Expiratory Volume in one second (FEV1) between 40% and 80% of the predicted value. Participants were randomly assigned to either the intervention group, which underwent an eight-week IMT program with TFRL, or the control group, which received general smoking cessation advice and no respiratory muscle training. The primary outcome measure is maximum inspiratory pressure (MIP), assessed using a handheld portable manometer. Secondary outcomes include pulmonary function tests (FEV1, FVC, and PEFR), perceived dyspnea via the Modified Borg Scale, and changes in smoking behavior. All the outcomes were recorded at baseline and after eight weeks. Results: Statistical analyses revealed that the intervention group showed significant improvements in respiratory muscle strength and pulmonary function compared to the control group. The two-way repeated measures ANOVA confirmed significant group-by-time interactions for MIP and pulmonary function tests, indicating that the changes over time differed between the intervention and control groups. Conclusion: IMT with TFRL may offer a valuable therapeutic approach for smokers suffering from lung impairment, particularly in non-pharmacological rehabilitation programs aimed at enhancing pulmonary function and reducing dyspnea.
inspiratory muscle trainingsmokersrespiratory muscle strengthlung function
International Journal of Physical Therapy Research & Practice · مجلد 3 (8) · 333-339
Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, often complicated by acute exacerbations that impair lung function and quality of life. Effective airway clearance techniques are essential in managing exacerbations, but the comparative effectiveness of different methods remains unclear. This study aimed to evaluate the short-term effectiveness of TheraPEP, a positive expiratory pressure (PEP) device, versus the Active Cycle of Breathing Technique (ACBT) in managing acute COPD exacerbations. Methods: A randomized controlled trial (RCT) was conducted with 60 patients (≥40 years) admitted with acute exacerbations of COPD. Participants were randomly assigned to either the TheraPEP group (n=30) or the ACBT group (n=30). Each group received three daily sessions of their assigned therapy throughout their hospital stay. Primary outcomes included dyspnea, measured by the modified Borg Dyspnea Scale, and secondary outcomes included sputum clearance, lung function (FEV1, FVC, and FEV1/FVC ratio), oxygen saturation (SpO₂), and quality of life, measured by the Breathlessness, Cough, and Sputum Scale (BCSS). Data were collected at baseline, discharge, and 14-day follow-up. A two-way repeated-measures ANOVA was used to examine changes in dyspnea, lung function, sputum clearance, SpO₂, and BCSS scores over time (baseline, discharge, and 14-day follow-up) within and between groups. The main effects of time (within-subject factor) and group (between-subject factor) were assessed, along with the interaction effects (time × group). Results: Both groups demonstrated significant improvements in dyspnea, lung function, and quality of life from baseline to discharge and follow-up. However, the TheraPEP group showed significantly greater improvements in sputum clearance (p=0.01), oxygen saturation (p=0.03), and BCSS scores (p=0.03) compared to the ACBT group. No significant between-group differences were found for FEV1, FVC, or FEV1/FVC ratio (p > 0.05). Conclusions: Both TheraPEP and ACBT are effective in managing acute COPD exacerbations, but TheraPEP offers additional benefits in terms of sputum clearance and oxygenation. These findings suggest that TheraPEP may be more suitable for patients with severe mucus hypersecretion. Further research is warranted to assess the long-term effects of these therapies on COPD progression and patient outcomes.